Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Oct 28, 2009; 15(40): 5058-5066
Published online Oct 28, 2009. doi: 10.3748/wjg.15.5058
Published online Oct 28, 2009. doi: 10.3748/wjg.15.5058
Table 4 Toxicity and UGT1A1 status according to treatment arm n (%)
| Toxicity WHO | mFOLFIRI | mIROX | χ² test | ||||||
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | ||
| WT (6/6) | 2 (33.3) | 10 (33.3) | 6 (37.5) | 1 (33.3) | - | 17 (53.1) | 3 (23.1) | 2 (50.0) | P > 0.05 |
| (6/7) | 3 (50.0) | 16 (53.3) | 7 (43.8) | 2 (66.7) | 1 (100) | 14 (43.8) | 7 (53.8) | 2 (50) | P > 0.05 |
| (7/7) | 1 (16.7) | 4 (13.3) | 2 (12.5) | - | - | 1 (3.1) | 2 (15.4) | - | P > 0.05 |
| (5/7) | - | - | 1 (6.3) | - | - | - | 1 (7.7) | - | P > 0.05 |
-
Citation: Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, Stemmler HJ.
UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J Gastroenterol 2009; 15(40): 5058-5066 - URL: https://www.wjgnet.com/1007-9327/full/v15/i40/5058.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.5058